Suppr超能文献

利用放射学报告的自然语言处理评估晚期黑色素瘤患者的生存率

Natural Language Processing of Radiology Reports to Assess Survival in Patients with Advanced Melanoma.

作者信息

Das Jeeban P, Eichholz Jordan, Sevilimedu Varadan, Gangai Natalie, Khalil Danny N, Postow Michael A, Do Richard K G

机构信息

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10017, USA.

出版信息

Cancers (Basel). 2025 May 7;17(9):1595. doi: 10.3390/cancers17091595.

Abstract

: To use natural language processing (NLP) to extract large-scale data from the CT radiology reports of patients with advanced melanoma treated with immunotherapy and to determine whether liver metastases affect survival. : Patient criteria (M1 disease subclassified into M1a, M1b, or M1c) as well as alternative criteria (M1 with advanced melanoma, imaged with CT chest, abdomen, and pelvis from July 2014-March 2019) were included retrospectively. NLP was used to identify metastases from CT reports, and then patients were classified according to American Joint Committee on Cancer (AJCC) staging disease subclassified into M1L+ or M1L-, indicating whether liver metastases were present or not). Statistical analysis included constructing Kaplan-Meier survival curves and calculating hazard ratios (HRs). : 2239 patients were included (mean age, 63 years). Whether using AJCC or alternative criteria, overall survival (OS) was poorest for M1L+ (entire cohort median OS, 0.69 years [95% CI: 0.60-0.82]; immunotherapy cohort median OS, 1.4 years [95% CI: 0.92-2.0]) compared to M1L- (entire cohort median OS, 1.8 years [95% CI: 1.4-2.2]; immunotherapy cohort median OS; M1L-, 2.9 years [95% CI: 2.3-3.9]). The median HR for M1L+ (median HR, 5.35 [95% CI: 4.59-6.24]) was higher than that for M0 ( < 0.001). The median HR for M1L+ (median HR, 2.13 [95% CI: 1.65-2.64]) was higher than that for M0 ( < 0.01). : Patients with advanced melanoma, particularly those with liver metastases, demonstrated inferior survival, even when treated with immunotherapy.

摘要

使用自然语言处理(NLP)从接受免疫治疗的晚期黑色素瘤患者的CT放射学报告中提取大规模数据,并确定肝转移是否影响生存。回顾性纳入患者标准(M1疾病细分为M1a、M1b或M1c)以及替代标准(2014年7月至2019年3月接受胸部、腹部和骨盆CT成像的晚期黑色素瘤M1患者)。使用NLP从CT报告中识别转移灶,然后根据美国癌症联合委员会(AJCC)分期将患者分类为M1L+或M1L-(表明是否存在肝转移)。统计分析包括构建Kaplan-Meier生存曲线和计算风险比(HRs)。纳入2239例患者(平均年龄63岁)。无论使用AJCC标准还是替代标准,M1L+患者的总生存期(OS)最差(整个队列的中位OS为0.69年[95%CI:0.60 - 0.82];免疫治疗队列的中位OS为1.4年[95%CI:0.92 - 2.0]),而M1L-患者(整个队列的中位OS为1.8年[95%CI:1.4 - 2.2];免疫治疗队列的中位OS;M1L-为2.9年[95%CI:2.3 - 3.9])。M1L+的中位HR(中位HR为5.35[95%CI:4.59 - 6.24])高于M0(<0.001)。M1L+的中位HR(中位HR为2.13[95%CI:1.65 - 2.64])高于M0(<0.01)。晚期黑色素瘤患者,尤其是有肝转移的患者,即使接受免疫治疗,生存期也较差。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6bf/12071518/e701a5e278b9/cancers-17-01595-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验